SCHEMBL8344634

SCHEMBL8344634

COc1cccc(-n2nc(C(C)C)c3c(NN)ncnc32)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GSK3B P49841 14/20 0.66
▸ PIK3CD O00329 3/20 0.47
▸ KDM4E B2RXH2 1/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ NPC1 O15118 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ HPGD P15428 1/20 0.43
▸ XBP1 P17861 1/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ NPSR1 Q6W5P4 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.43
▸ PI4KB Q9UBF8 2/20 0.42
▸ SRC P12931 2/20 0.42
▸ ABL1 P00519 1/20 0.42
▸ EGFR P00533 1/20 0.42
▸ HCK P08631 1/20 0.42
▸ KDR P35968 1/20 0.42
▸ PIK3CA P42336 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8338999 0.83 GSK3B (0.61) GSK3BPIK3CDKDM4EMEN1NPC1
SCHEMBL8344172 0.83 GSK3B (0.58) GSK3BPIK3CDKDM4EMEN1NPC1
SCHEMBL6207166 0.82 GSK3B (0.66) GSK3BKDM4EMEN1NPC1ALDH1A1
SCHEMBL6251627 0.81 GSK3B (0.66) GSK3BKDM4EMEN1NPC1ALDH1A1
SCHEMBL8342631 0.80 GSK3B (1.00) GSK3BGSK3A
SCHEMBL8344397 0.78 GSK3B (0.78) GSK3BGSK3A
SCHEMBL8342463 0.75 GSK3B (0.75) GSK3BGSK3A
SCHEMBL6203816 0.74 MAPT (0.68) GSK3BKDM4EMEN1NPC1ALDH1A1
SCHEMBL6205168 0.67 GSK3B (0.61) GSK3BPIK3CDMEN1NPC1MAPT
SCHEMBL8339887 0.67 GSK3B (0.62) GSK3BPIK3CDKDM4EMEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004009602-A1 PYRAZOLOPYRIMIDINES AS KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2004-01-29 — — WO disclosed
Send feedback